Search results
15 wrz 2022 · Abstract. Despite the many advances in cardiovascular medicine, decisions concerning the diagnosis, prevention, and treatment of left ventricular (LV) thrombus often remain challenging. There are only limited organizational guideline recommendations with regard to LV thrombus.
- View EPUB
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Linda S. Williams
Many diseases with specific indications for specific...
- PDF/Epub
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Trial
Background—The Randomized Evaluation of Long-term...
- Results From the GEIST
Left ventricular (LV) thrombus formation is a well‐known...
- Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome
Objective: Takotsubo syndrome (TTS) is characterized by...
- Stroke
National Center. 7272 Greenville Ave.Dallas, TX 75231....
- Peripartum Cardiomyopathy
Peripartum cardiomyopathy is a potentially life-threatening...
- View EPUB
14 wrz 2022 · We suggest that, on the basis of limited data, patients with NICM with LV thrombus should be treated with OAC for at least 3–6 mo, with dis-continuation if LVEF improves to >35% (assuming resolution of the LV thrombus) or if major bleeding occurs.
1 maj 2023 · Echocardiographic outcomes evaluated included resolution of thrombus size and time to complete thrombus resolution. Clinical outcomes included mortality, thromboembolic complications, and bleeding complications.
23 wrz 2022 · If OAC is initiated, a treatment duration might be 1–3 months, depending on bleeding risk. On the basis of reasonable data and evidence, post-MI patients with LV thrombus should be treated with OAC, typically for a duration of 3 months.
Management of LV thrombus (LVT) is challenging and crucial to prevent the potential development of thromboembolic complications such as stroke. Anticoagulation with warfarin is recommended for the prevention of thromboembolic events, but novel oral anticoagulants (NOAC) have been used in clinical practice without supporting evidence.
The presence of a left ventricular thrombus in a patient with severe coronary artery disease poses a difficult clinical decision regarding safety, effectiveness, timing, and type of coronary revascularization.
Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality. Traditionally, LV thrombus has been associated with acute myocardial infarction (MI).
